Genmab acquieres worldwide rights for HUMAX-CD4
Under the terms of the agreement, Genmab has agreed to pay Medarex an upfront payment of USD 2 million, and Medarex is entitled to potential total milestone and license fee payments of USD 12.5 million, as well as royalties that could reach double digits for a successfully commercialized product in the new territories.
"We believe that consolidating the worldwide rights to HuMax-CD4 should help us leverage more value from our development work to date. We can build on that to move forward in Europe where we already have an orphan drug designation," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous